Table 1.
Clinical studies investigating the role of cardiac troponins and pro-brain natriuretic peptide in anthracycline-induced cardiotoxicity
| Refs. | Author | Cancer type | N | Age (year) | AC analog | AC dose (mg/m2) | Time interval | Cardiac troponins | Pro-BNP |
|---|---|---|---|---|---|---|---|---|---|
| [4] | Ky (2014) | Breast cancer | 78 | 50 | Doxorubicin | 60 | 0, 3, 6, 15 m | SE (TnI) Significant after 3 m with a 23.4% predictive value |
NSE |
| [5] | Sawaya (2012) | Breast cancer | 81 | 50 ± 10 | Doxorubicin Epirubicin | 240 300 |
0, 3, 6, 15 m | SE (cTnI) Significant in low and high dose groups |
NSE |
| [11] | Broeyer (2008) | Various malignancies | 26 | 46 ± 15 | Doxorubicin Variable AC |
520 | 0, 4, 24 h | NSE | SE |
| [24] | Armenian (2014) | Hematologic malignancies | 100 (HR) 50 (LR) |
26.6 20.8 |
Variable AC | <300 >300 |
>10 year >10 year |
NSE | SE |
| [25] | Cardinale (2004) | Various malignancies | 703 | 47 ± 12 | High dose chemotherapy | – | 1, 3, 6, 9, 12 m | SE (cTnI) |
– |
| [29] | Dodos (2008) | Hematologic malignancies | 100 | 70 | Doxorubicin | >300 | 24 h, 12 m | NSE (TnI) |
NSE |
| [30] | Feola (2009) | Breast cancer | 53 | 55.3 | Doxorubicin | 60 | 0, 1, 2, 3 m | Significant elevation after 1 month followed by steady non-significant decrease (TnI) | SE |
| [34] | Romano (2011) | Breast cancer | 71 | 18–75 | Doxorubicin Epirubicin | 300 540 |
Day 1-6, 3, 6, 12 m | NSE | SE |
| [48] | Harake (2012) | Hematologic malignancies | 100 | >18 | Doxorubicin | 300 | 0 and 3 m | SE (TnT) High dose |
SE High dose |
| [51] | Putt (2015) | Breast cancer | 78 | <18 | Doxorubicin | 0, 3, 6, 15 m | SE (TnI) |
NSE | |
| [54] | Oliveira-Carvalho (2015) | Breast cancer | 59 | – | Doxorubicin | 60 | 0, 3, 6, 9, 12 m | SE (TnI) |
– |
AC anthracyclines, m month, LOE level of evidence, NSE No Significant Elevation of Serum Biomarker and Association with Cardiotoxicity, SE Significant Elevation of Serum Biomarker and Association with Cardiotoxicity, y years, HR high risk, LR low risk